Aspen Neuroscience, Inc. (ASPE)
| Market Cap | 336.58M |
| Revenue (ttm) | n/a |
| Net Income | -66.84M |
| EPS | -6.29 |
| Shares Out | 29.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 185,344 |
| Open | 12.21 |
| Previous Close | 12.76 |
| Day's Range | 11.58 - 12.70 |
| 52-Week Range | 11.20 - 14.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ASPE
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Asp... [Read more]
Financial Performance
Financial StatementsNews
Aspen Neuroscience Announces Pricing of Initial Public Offering
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson's ...
Aspen Neuroscience Registration statement: Registration filing
Aspen Neuroscience filed a registration statement on October 26, 2026, providing details about a securities offering with the SEC.
Aspen Neuroscience Registration statement: Registration filing
Aspen Neuroscience filed a registration statement on October 22, 2026, providing details about a securities offering with the SEC.
Parkinsons-focused Aspen and bispecific biotech Bambusa plan IPOs
Parkinsons disease cell therapy-focused Aspen Neuroscience and bispecific biotech
Parkinsons disease biotech Aspen Neuroscience files for a $100 million IPO
Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinsons disease, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Aspen Neuroscience IPO Registration Document (S-1)
Aspen Neuroscience has filed to go public with an IPO on the NASDAQ
Aspen Neuroscience Registration statement: Registration filing
Aspen Neuroscience filed a registration statement on October 9, 2026, providing details about a securities offering with the SEC.